MedTrace Logo

Psilocybin Therapy for Depression in Bipolar II Disorder

NCT05065294 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-09-25

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.

Conditions

  • Bipolar II Disorder

Interventions

DRUG

Psilocybin therapy

\- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring

Sponsors & Collaborators

Principal Investigators

  • Joshua D Woolley, MD,PhD · University of California, San Francisco

  • David Guard, PhD · San Francisco State University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-28
Primary Completion
2024-08-01
Completion
2025-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05065294 on ClinicalTrials.gov